低LDL-C/HDL-C比值与脑出血后不良临床结局相关:中国多中心前瞻性队列数据的回顾性分析
本研究基于中国北京13家医院2014年1月至2016年9月的前瞻性观察队列数据,回顾性分析491例自发性脑出血患者。按LDL-C/HDL-C比值四分位分组,最低组(<1.74)相比最高组(>3.16)的30天不良功能结局调整OR为3.61(95%CI 1.68-7.72),90天为2.82(95%CI 1.33-5.95)。限制性立方样条显示非线性关联,比值3.1-3.5与90天功能结局较好相关。低比值与90天全因死亡无显著相关。
要点
- 491例自发性脑出血患者中,LDL-C/HDL-C比值最低四分位组(<1.74)相比最高四分位组(>3.16),30天不良功能结局(mRS 3-6)调整OR为3.61(95%CI 1.68-7.72)。
- 同一比较中,90天不良功能结局调整OR为2.82(95%CI 1.33-5.95),提示低LDL-C/HDL-C比值与远期功能不良独立相关。
- 限制性立方样条显示LDL-C/HDL-C比值与90天不良功能结局呈非线性关联,比值3.1-3.5与最低风险相关。
- 低LDL-C/HDL-C比值与90天全因死亡无显著相关。
- 研究为回顾性分析多中心前瞻性队列数据,仅纳入有入院血脂信息的患者,结论需进一步验证。
适用人群与场景
- 自发性脑出血患者,来自中国北京13家医院2014年1月至2016年9月的前瞻性观察队列,最终纳入491例有入院血清血脂信息的患者。
- 平均年龄57.6岁,男性占72.1%(357/491)。
诊断标准与关键阈值
- 采用LDL-C/HDL-C比值四分位分组:最低四分位组<1.74,最高四分位组>3.16。
- 不良功能结局定义为改良Rankin量表(mRS)评分3-6分。
研究设计与关键结果
- 研究类型为基于多中心前瞻性观察队列数据的回顾性分析,最终纳入491例自发性脑出血患者。
- 主要结局:与最高四分位组(>3.16)相比,最低四分位组(<1.74)的30天不良功能结局调整OR为3.61(95%CI 1.68-7.72),90天不良功能结局调整OR为2.82(95%CI 1.33-5.95)。
- 限制性立方样条显示LDL-C/HDL-C比值与90天不良功能结局呈非线性关联,比值3.1-3.5与更好的90天功能结局相关。
- 低LDL-C/HDL-C比值与90天全因死亡无显著相关。
证据类型、等级与局限
- 证据类型:基于多中心前瞻性观察队列数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,较低的LDL-C/HDL-C比值(<1.74)与脑出血患者不良功能结局风险增加独立相关。
- 作者认为,在其研究人群中,LDL-C/HDL-C比值与90天不良功能结局呈非线性关联,比值3.1-3.5的患者90天不良功能结局风险似乎最低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The association between low-density lipoprotein cholesterol (LDL-C)/high-density lipoprotein cholesterol (HDL-C) ratio and the clinical outcomes of acute intracranial hemorrhage (ICH) remains unclear. In this study, we attempt to investigate whether low LDL-C/HDL-C ratio is associated with poor clinical outcomes in patients with ICH.
METHODS: The database was collected from a multicenter, prospective, observational cohort study, conducted in 13 hospitals in Beijing from January 2014 to September 2016. A total of 1,964 patients with ICH were initially screened in our database. Next, we selected patients with admission serum lipid information for retrospective analysis. Patients were categorized into four groups based on LDL-C/HDL-C ratio quartiles. The main outcomes were 30-day and 90-day poor functional outcome, which is defined as modified Rankin Scale score of 3 to 6, and 90-day all-cause death. Logistic regression was used to assess the association between LDL-C/HDL-C ratio and 30-day or 90-day poor functional outcome. Kaplan-Meier survival analysis and Cox regression were used to assess the association between LDL-C/HDL-C ratio and 90-day all-cause death. Restricted cubic splines were used to explore the nonlinear association between LDL-C/HDL-C ratio and the outcome of patients with ICH.
RESULTS: A total of 491 patients with spontaneous ICH were finally enrolled in our study. The mean age was 57.6 years old, and 72.1% (357/491) were men. After adjustment for confounders, patients in the lowest LDL-C/HDL-C quartile (< 1.74) had a significantly higher risk of 30-day and 90-day poor functional outcome compared with those in the highest quartile (> 3.16; 30-day: adjusted odds ratio 3.61, 95% confidence interval 1.68-7.72; 90-day: adjusted odds ratio 2.82, 95% confidence interval 1.33-5.95). Restricted cubic splines depicted a nonlinear association between LDL-C/HDL-C ratio and 90-day poor functional outcomes, indicating LDL-C/HDL-C ratio of 3.1-3.5 was correlated with better 90-day functional outcome. However, no significant correlation was found between low LDL-C/HDL-C ratio and 90-day all-cause death.
CONCLUSIONS: Lower LDL-C/HDL-C ratio (< 1.74) is independently associated with an increased risk of poor functional outcome in patients with ICH. In the population of patients whom we studied, there is a nonlinear association between LDL-C/HDL-C ratio and 90-day poor functional outcome, and patients with an LDL-C/HDL-C ratio of 3.1 to 3.5 tend to have the lowest risk of 90-day poor functional outcome.
参考来源
- Wu L, Wang A, Kang K, et al. Low LDL-C/HDL-C Ratio is Associated with Poor Clinical Outcome After Intracerebral Hemorrhage: A Retrospective Analysis of Multicenter, Prospective Cohort Data in China. Neurocrit Care. 2023. PMID: 38148436. doi:10.1007/s12028-023-01905-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。